FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
	ber: 3235-0287								
OMB Number:	3235-0287								
Estimated average b	ourden								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

1. Name and Address of Reporting Person* Cheng Andrew (Last) (First) (Middle) C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 (Street) SOUTH SAN						2. Issuer Name and Ticker or Trading Symbol Akero Therapeutics, Inc. [AKRO] 3. Date of Earliest Transaction (Month/Day/Year) 10/03/2022 4. If Amendment, Date of Original Filed (Month/Day/Year)								S. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title Other (specify below) President & CEO 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
FRANCI (City)	ISCO C	tate)	94080 (Zip)											Form 1 Persoi	iled by Moi า		One Repor		
Table I - No 1. Title of Security (Instr. 3)			on-Derivative S 2. Transaction Date (Month/Day/Year)		ion 2A. Deemed Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			d (A) or	5. Amount of Securities Beneficially Owned Following		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)		
Common	Stock			10/03	3/2022	1			M ⁽¹⁾		10,000	A	\$0.61		0,148 D				
Common					3/2022	-			S ⁽¹⁾		4,550	D	\$32.80	_	315,598				
Common				-	3/2022	_			S ⁽¹⁾		5,350	D	\$33.57		, -				
Common	Common Stock 10/03/				3/2022	2022			S ⁽¹⁾		100	D	\$34.39	9 310	310,148		D		
		-	Table II								osed of, convertil			Owned					
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deeme Execution if any (Month/Day	n Date,		ransaction Code (Instr.		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			d Amount ies g Security nd 4)	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	ode V			Date Exercisa	ıble	Expiration Date	Title	Amount or Number of Shares	ber					
Stock Option (Right to Buy)	\$0.615	10/03/2022			M ⁽¹⁾			10,000	(4)		10/17/2028	Common Stock	10,000	\$0.00 230,868		58	D		

Explanation of Responses:

- 1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person.
- 2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$32.28 to \$33.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.28 to \$34.00, inclusive.
- 4. The options are vested and currently exercisable.

Remarks:

/s/ Jonathan Young, Attorneyin-Fact ** Signature of Reporting Person

10/05/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.